Syndax Pharmaceuticals, Inc. is starting out with a rare subset of acute leukemia patients when it submits revumenib for US Food and Drug Administration review at the end of the year, but it is also aiming for a larger subset that could potentially yield a blockbuster opportunity, one in which others hope to compete as well.
Syndax’s Revumenib Makes Splash At ASH As Company Eyes Blockbuster Opportunity
The company presented data for the menin inhibitor in KMT2Ar acute leukemias in an ASH late-breaker. The larger addressable population, including mNPM1 AML, could be a $2bn opportunity.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from Conferences
• By
The founder and director of City Therapeutics and founding CEO of Alnylam discussed pressing issues facing the biotech sector in a fireside chat at the recent BIO CEO & Investor Conference.
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.